Revisions to the international guidelines on the diagnosis and therapy of chronic urticaria

@article{Maurer2013RevisionsTT,
  title={Revisions to the international guidelines on the diagnosis and therapy of chronic urticaria},
  author={Marcus Maurer and Markus Magerl and Martin Metz and Torsten Zuberbier},
  journal={JDDG: Journal der Deutschen Dermatologischen Gesellschaft},
  year={2013},
  volume={11}
}
At the end of 2012, more than 300 participants discussed and agreed on the update of the international guidelines on urticaria at the 4th International Consensus Meeting (URTICARIA 2012). Currently, the recommendations are in the final process of international coordination. In preparation for the update, questions were prepared by an expert panel; this was followed by a systematic literature search. The questions and the resulting recommendations were discussed by the participants and decided… Expand
KAAACI Work Group report on the management of chronic urticaria
TLDR
The epidemiology, pathogenesis, diagnosis, and management based on case reports and studies of CU from Korea and the other part of world, and recently published guidelines are reviewed and summarized. Expand
Management of chronic inducible urticaria according to the guidelines: A prospective controlled study.
TLDR
CIndU seem to be more resistant to standard doses ofAHs and higher doses of AHs are required for the control of symptoms. Expand
Chronic spontaneous urticaria – a management pathway for patients with chronic spontaneous urticaria
TLDR
A working group composed of dermatologists in private practice and specialized urticaria centers has defined a practical pathway for the implementation of current treatment recommendations based on the 2013 S3 guidelines for CSU, to provide physicians inprivate practice with a practical guideline‐based therapeutic decision tool. Expand
[Diagnostic and Therapeutic Approach of Chronic Spontaneous Urticaria: Recommendations in Portugal].
TLDR
Of the two options, omalizumab and cyclosporine, only omalIZumab is approved for chronic spontaneous urticaria and has a better safety profile, thus being preferably recommended. Expand
Urticaria in children: pathogenetic mechanisms and the possibilities of modern therapy
TLDR
It is notorious that histamine-liberation lies in the basis of the disease pathogenesis, regardless of the cause provoking an exacerbation, which explains the unified principle of therapy for all variants of urticaria - the administration of non-sedating antihistamines in the first line. Expand
Commentary: Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria
  • R. Sabroe
  • Medicine
  • The British journal of dermatology
  • 2014
TLDR
The primary and secondary end points listed were amended to correspond to the published article almost 6 months after publication, and the significance and timing of such changes is relevant. Expand
Urticaria in children and adolescents: An updated review of the pathogenesis and management
TLDR
It has been observed that urticaria occurs less often in children than adults, with symptoms rarely lasting for over 6 weeks, and medical experts recommend using the same treatment schemes for adults and children. Expand
Chronic Urticaria: An Overview of Treatment and Recent Patents
TLDR
Omalizumab has been a remarkable advancement in the management of CU and improves the quality of life beyond symptom control and is idiopathic in the majority of cases. Expand
Clinical practice guideline for diagnosis and management of urticaria.
TLDR
Non-pharmacotherapeutic means to minimize hyper-responsive skin are also important and recommended, such as prevention skin from drying, avoidance of hot shower, scrubbing, and excessive sun exposure. Expand
Physical urticaria: Review on classification, triggers and management with special focus on prevalence including a meta-analysis
TLDR
The results suggest that PU is an important subset of CU and that physicians should be aware of this important condition in order to manage patients appropriately and to estimate the prevalence of PU in CU patients. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 27 REFERENCES
EAACI/GA2LEN/EDF guideline: management of urticaria
TLDR
The recommended first line treatment are nonsedating H1 antihistamines, but dosages increased up to fourfold over the recommended doses may be necessary for different urticaria subtypes and in view of individual variation in the course of the disease and response to treatment. Expand
EAACI/GA²LEN/EDF/WAO guideline: management of urticaria
TLDR
This guideline has a profound impact on the quality of life and effective treatment is, therefore, required and the recommended first line treatment is new generation, nonsedating H1‐antihistamines, and second‐line therapies should be added to the antihistamine treatment. Expand
EAACI/GA2LEN/EDF/WAO Guideline:Management of Urticaria
TLDR
The recommended first line treatment of urticaria is new generation, nonsedating H1-antihistamines, and second-line therapies should be added to the antihistamine treatment, both their costs and risk/benefit profiles are most important to consider. Expand
Low-dose cyclosporine is a good option for severe chronic urticaria.
TLDR
The referral center has evaluated too many patients treated with steroids before antihistamine responsiveness has been determined properly, and the referral center would not wish to use cyclosporine in someone who might respond to hydroxyzine, particularly because the experience at 2mg/kg is not nearly as good as that at 3 mg/kg for initial therapy. Expand
How to assess disease activity in patients with chronic urticaria?
TLDR
This data indicates that the current EAACI/GA²LEN/EDF guidelines recommend assessing disease activity in chronic urticaria by using an established and well‐defined symptom score, but this UAS has never been formally tested for its suitability in assessing CU activity. Expand
Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy.
TLDR
Omalizumab was well tolerated and reduced the signs and symptoms of CIU/CSU in patients who remained symptomatic despite the use of H₁-antihistamines, leukotriene receptor antagonists, or both. Expand
Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria.
TLDR
Omalizumab diminished clinical symptoms and signs of chronic idiopathic urticaria in patients who had remained symptomatic despite the use of approved doses of H-antihistamine therapy (licensed doses). Expand
EAACI/GA2LEN/EDF/WAO guideline: definition, classification and diagnosis of urticaria
TLDR
This guideline covers the definition and classification of urticaria, taking into account the recent progress in identifying its causes, eliciting factors, and pathomechanisms, and outlines evidence‐based diagnostic approaches for different subtypes ofUrticaria. Expand
Randomized double‐blind study of cyclosporin in chronic ‘idiopathic’ urticaria
TLDR
This study shows that cyclosporin is effective for chronic urticaria and provides further evidence for a role of histamine‐releasing autoantibodies in the pathogenesis of this chronic ‘idiopathic’ disease. Expand
Cyclosporine in chronic idiopathic urticaria: a double-blind, randomized, placebo-controlled trial.
TLDR
CsA in addition to background therapy with cetirizine may be useful in the treatment of CIU, and symptom scores significantly improved in both CsA groups over with placebo. Expand
...
1
2
3
...